Education and Research Center of Animal Models for Human Diseases, Fujita Health University, Toyoake, Aichi 4701192, Japan.
PPAR Res. 2012;2012:695898. doi: 10.1155/2012/695898. Epub 2012 May 13.
Kidneys are enlarged by aberrant proliferation of tubule epithelial cells leading to the formation of numerous cysts, nephron loss, and interstitial fibrosis in polycystic kidney disease (PKD). Pioglitazone (PIO), a PPAR-γ agonist, decreased cell proliferation, interstitial fibrosis, and inflammation, and ameliorated PKD progression in PCK rats (Am. J. Physiol.-Renal, 2011). To explore genetic mechanisms involved, changes in global gene expression were analyzed. By Gene Set Enrichment Analysis of 30655 genes, 13 of the top 20 downregulated gene ontology biological process gene sets and six of the top 20 curated gene set canonical pathways identified to be downregulated by PIOtreatment were related to cell cycle and proliferation, including EGF, PDGF and JNK pathways. Their relevant pathways were identified using the Kyoto Encyclopedia of Gene and Genomes database. Stearoyl-coenzyme A desaturase 1 is a key enzyme in fatty acid metabolism found in the top 5 genes downregulated by PIO treatment. Immunohistochemical analysis revealed that the gene product of this enzyme was highly expressed in PCK kidneys and decreased by PIO. These data show that PIO alters the expression of genes involved in cell cycle progression, cell proliferation, and fatty acid metabolism.
肾脏由于小管上皮细胞的异常增殖而肿大,导致多囊肾病 (PKD) 中形成许多囊肿、肾单位丧失和间质纤维化。吡格列酮 (PIO) 是一种过氧化物酶体增殖物激活受体-γ 激动剂,可减少细胞增殖、间质纤维化和炎症,并改善 PCK 大鼠的 PKD 进展(美国生理学杂志-肾脏,2011 年)。为了探索涉及的遗传机制,分析了全局基因表达的变化。通过对 30655 个基因的基因集富集分析,前 20 个下调基因本体生物学过程基因集中的 13 个和前 20 个经修饰的基因集经典途径中的 6 个被鉴定为 PIO 治疗下调的与细胞周期和增殖有关,包括 EGF、PDGF 和 JNK 途径。使用京都基因与基因组百科全书数据库确定了它们的相关途径。硬脂酰辅酶 A 去饱和酶 1 是脂肪酸代谢中的关键酶,在 PIO 治疗下调的前 5 个基因中表达下调。免疫组织化学分析显示,该酶的基因产物在 PCK 肾脏中高度表达,并被 PIO 下调。这些数据表明 PIO 改变了参与细胞周期进程、细胞增殖和脂肪酸代谢的基因的表达。